文献速递传染病防控与疫情报告免疫规划

伤寒结合疫苗在巴基斯坦 extensively drug-resistant 暴发中的有效性:队列研究

Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
PubMed 文献 · Lancet Glob Health · 2021-01-01

该队列研究在巴基斯坦海得拉巴的广泛耐药伤寒暴发地区评估Typbar-TCV对6月龄至10岁儿童的保护效果。结果显示,疫苗对培养确诊伤寒的有效性为95%(95%CI 93-96),对广泛耐药菌株为97%(95%CI 95-98),对疑似伤寒为55%(95%CI 52-57)。

要点

  • Typbar-TCV对培养确诊伤寒有效性95%,对广泛耐药株97%。
  • 对疑似伤寒(不论培养确诊)有效性为55%。
  • 在暴发环境中中度接种即可遏制广泛耐药伤寒流行。

核心结论

  • Typbar-TCV在广泛耐药伤寒暴发环境中对儿童具有保护效果,且不依赖抗菌药物耐药性。

研究设计与样本

  • 前瞻性队列研究,2018年2月21日至2019年12月31日在巴基斯坦海得拉巴Qasimabad和Latifabad两个分区开展,基线登记174 005户家庭,接种207 000名6月龄至10岁儿童,通过主动监测和随机抽样队列评估结局。

主要发现

  • 疫苗对疑似伤寒有效性55%(95%CI 52-57),对培养确诊伤寒95%(95%CI 93-96),对广泛耐药伤寒97%(95%CI 95-98)。

临床怎么用

  • 在伤寒暴发尤其广泛耐药株流行区,可考虑使用Typbar-TCV开展儿童接种以控制疫情。

局限性

  • 研究为观察性队列设计,可能存在未测量混杂;疫苗有效性针对特定暴发环境和年龄组,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salmonella enterica serotype Typhi (S Typhi) is a major public health problem in low-income and middle-income countries. We aimed to investigate the effectiveness and impact of the typhoid conjugate vaccine Typbar-TCV against S Typhi among children in an outbreak setting of extensively drug-resistant (XDR) S Typhi in Pakistan. METHODS: This cohort study was done from Feb 21, 2018, to Dec 31, 2019. A census survey of all households located in the Qasimabad and Latifabad subdistricts of Hyderabad, Pakistan, was done at baseline, and 174 005 households were registered in the census. The Typbar-TCV immunisation campaign was initiated at temporary vaccination centres and 207 000 children aged 6 months to 10 years were vaccinated from Feb 21, 2018, to Dec 31, 2018. Social mobilisers informed parents about the vaccination process. Vaccination records were maintained electronically and linked with the household census surveys. Active surveillance for suspected and blood-culture-confirmed S Typhi was established in hospitals, clinics, and laboratories to assess the following outcomes: cases of suspected typhoid fever, culture-confirmed S Typhi, and antimicrobial resistance. An age-stratified cohort of 1100 vaccinated children was randomly selected from the vaccination registry, tested for Vi-IgG antibodies (data not reported), and followed up fortnightly (via telephone calls or household visits) until Dec 31, 2019, for ascertainment of outcomes during the study period. 20 847 vaccinated and unvaccinated children were randomly selected from the census registry as a quality control cohort and followed up from Oct 1 to Dec 31, 2019, for ascertainment of outcomes. Vaccine effectiveness against suspected, culture-confirmed, and XDR S Typhi was calculated. FINDINGS: 23 407 children from the census registry and surveillance system were included in the vaccine effectiveness analysis. 13 436 (57·4%) children were vaccinated, 12 214 (52·2%) were male, and 10 168 (43·4%) were aged 6-59 months. 5378 (23·0%) of 23 407 children had suspected S Typhi, among whom 775 (14·4%) had culture-confirmed S Typhi and 361 (68·6%) of 526 had XDR S Typhi. Vaccine effectiveness was 55% (95% CI 52-57) against suspected S Typhi (regardless of culture confirmation), 95% (93-96) against culture-confirmed S Typhi, and 97% (95-98) against XDR S Typhi. INTERPRETATION: Typbar-TCV is effective in protecting children against S Typhi infection in an outbreak setting, and was able, with moderate deployment, to curtail a major XDR S Typhi outbreak in a densely populated setting. The vaccine shows efficacy against S Typhi irrespective of antimicrobial resistance. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Yousafzai MT, Karim S, Qureshi S, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health. 2021. PMID: 34297962. doi:10.1016/S2214-109X(21)00255-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。